Close Menu

NEW YORK (GenomeWeb) – Illumina expects its third quarter 2015 revenues to be lower than originally anticipated and has lowered its expected full-year revenue growth to 18 percent from its previous estimate of 20 percent, the company said after the close of the market today.

Illumina reported preliminary Q3 revenues of $550 million, a 14 percent increase from $481 million in the third quarter of 2014, but below analysts' average estimate of $568.6 million. On a constant currency basis, Q3 revenues were up 18 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.